"I think it could be impactful,"
"Their challenge is going to be who has more power and influence over the industry, the PBMs/insurance companies and the contracts they have with brand manufacturers, or the President. That has not been determined yet."
"most-favored-nation"
The Trump administration plans to launch TrumpRx.gov to sell prescription drugs directly to consumers, with the website expected to go live in early 2026. The administration is partnering with Pfizer to offer drugs at direct-to-consumer cost averaging about 50% savings, and the partnership gives Pfizer a three-year reprieve from expected pharmaceutical tariffs. The initiative advances a "most-favored-nation" pricing approach to align U.S. drug prices with other countries. Mark Cuban founded Cost Plus Drugs in 2022 to sell discounted generics by bypassing PBMs, and he said the plan could be impactful while noting PBM and insurer influence is a key challenge. U.S. drug prices were 2.78 times higher than other OECD countries as of 2022.
Read at Fortune
Unable to calculate read time
Collection
[
|
...
]